25 Recruiting Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceTop Recruiting Clinical Stage III Cutaneous Melanoma AJCC v8 Studies
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
📍 Mayo Clinic in Rochester — Rochester, Minnesota
View Study & Checklist ➔Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
📍 Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee
View Study & Checklist ➔Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
📍 UC San Diego Moores Cancer Center — La Jolla, California
View Study & Checklist ➔Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View Study & Checklist ➔Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
View Study & Checklist ➔Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
📍 Moffitt Cancer Center - McKinley Campus — Tampa, Florida
View Study & Checklist ➔Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔